{
    "eid": "2-s2.0-85063186796",
    "title": "Pharmacogenomics: A new approach for preventing severe cutaneous adverse drug reactions",
    "cover-date": "2018-07-02",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Chonlaphat Sukasem",
        "Therdpong Tempark"
    ],
    "citedby-count": 2,
    "ref-count": 165,
    "ref-list": [
        "Mechanisms of drug-induced allergy",
        "Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy",
        "Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation",
        "Allergic reactions to drugs: involvement of T cells",
        "Human leukocyte antigens and drug hypersensitivity",
        "T cell-mediated hypersensitivity reactions to drugs",
        "Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back",
        "T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance",
        "Severe cutaneous adverse drug reactions",
        "Pathogenesis of drug allergy-current concepts and recent insights",
        "Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation",
        "Cutaneous drug hypersensitivity: immunological and genetic perspective",
        "Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children",
        "Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions",
        "Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population",
        "Genetic variants associated with phenytoin-related severe cutaneous adverse reactions",
        "Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin",
        "Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population",
        "Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians",
        "Medical genetics: a marker for Stevens-Johnson syndrome",
        "Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese",
        "Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan",
        "Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population",
        "Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant",
        "HLA-B*5701 screening for hypersensitivity to abacavir",
        "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol",
        "Impact of the HLA-B(*) 58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions",
        "HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand",
        "Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population",
        "Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response",
        "Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis",
        "Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis",
        "A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children",
        "Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management",
        "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis",
        "Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis",
        "Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel",
        "Statistical analysis of Stevens-Johnson syndrome caused by mycoplasma pneumonia infection in Japan",
        "Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience",
        "Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital",
        "Stevens-Johnson syndrome and toxic epidermal Necrolysis: an update",
        "Toxic epidermal necrolysis: Part II Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment",
        "HLA-B* 58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population",
        "Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome",
        "Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption",
        "Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis",
        "Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)",
        "Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series",
        "Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)",
        "Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses",
        "Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan",
        "DRESS syndrome: part I Clinical perspectives",
        "Drug reaction with eosinophilia and systemic symptoms syndrome",
        "Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms",
        "Anticonvulsant hypersensitivity syndrome In vitro assessment of risk",
        "Drug-reaction with eosinophilia and systemic symptoms (DRESS syndrome)",
        "Carbamazepineinduced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review",
        "Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients",
        "The DRESS syndrome: a literature review",
        "Is the drug-induced hypersensitivity syndrome (DIH) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review",
        "Severe adverse cutaneous reactions to drugs",
        "The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug",
        "Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome",
        "Fulminant myocarditis as a late sequela of DRESS: two cases",
        "Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides",
        "DRESS syndrome: part II Management and therapeutics",
        "Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review",
        "The lymphocyte transformation test in the diagnosis of drug hypersensitivity",
        "Management of drug reaction with eosinophilia and systemic symptoms (DRESS)",
        "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?",
        "Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases",
        "Clinical heterogeneity of drug hypersensitivity",
        "Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern",
        "Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)",
        "Profile of acute generalized exanthematous pustulosis in Israel during 2002-2005: results of the RegiSCAR study",
        "Acute generalized exanthematous pustulosis",
        "Acute generalized exanthematous pustulosis (AGEP): a review and update",
        "Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis",
        "Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl",
        "Case of acute generalized exanthematous pustulosis caused by ampicillin/cloxacillin sodium in a pregnant woman",
        "Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation",
        "T-cell involvement in drug-induced acute generalized exanthematous pustulosis",
        "Acute generalized exanthematous pustulosis: atypical presentations and outcomes",
        "Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group a confirmed by epicutaneous testing and lymphocyte transformation tests",
        "Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis",
        "Acute generalised exanthematous pustulosis",
        "Drug hypersensitivity: pharmacogenetics and clinical syndromes",
        "Delayed drug hypersensitivity reactions",
        "Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome",
        "Overview of the immune response",
        "Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis",
        "Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome",
        "Interaction of small molecules with specific immune receptors: the p-i concept and its consequences",
        "Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment",
        "HLA and TCR recognition of medications in severe cutaneous adverse reactions",
        "Immune self-reactivity triggered by drug-modified HLA-peptide repertoire",
        "Development of an incipient Stevens-Johnson reaction while on a stable dose of lamotrigine",
        "Data mining FAERS to analyze molecular targets of drugs highly associated with Stevens-Johnson syndrome",
        "Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study",
        "CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations",
        "The absence of CYP3A5*3 is a protective factor to anticonvulsants hypersensitivity reactions: a case-control study in Brazilian subjects",
        "HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis",
        "Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population",
        "Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China",
        "HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese",
        "HLA-B locus in Caucasian patients with carbamazepine hypersensitivity",
        "Absence of HLA-B*1502 and HLA-A*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash: a preliminary study",
        "Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis",
        "HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis",
        "HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children",
        "Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population",
        "Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans",
        "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans",
        "HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis",
        "Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions",
        "Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms",
        "The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population",
        "HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption",
        "HLA-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population",
        "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population",
        "Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis",
        "Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population",
        "Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS)",
        "HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican mestizo patients",
        "The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population",
        "Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese",
        "Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population",
        "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing",
        "Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population",
        "HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese",
        "Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population",
        "Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population",
        "Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012",
        "Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies",
        "HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study",
        "A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients",
        "In Silico analysis of interactions between HLA-B* 58:01 and allopurinol-related compounds",
        "Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility",
        "Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01",
        "Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing",
        "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir",
        "Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations",
        "Genetic variations in HLA-B region and hypersensitivity reactions to abacavir",
        "Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART",
        "High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients",
        "Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine",
        "Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions",
        "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs",
        "HLA-B*13:01 and the dapsone hypersensitivity syndrome",
        "Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population",
        "Stevens-Johnson syndrome induced by acetazolamide",
        "Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01",
        "Stevens-Johnson syndrome associated with methazolamide treatment reported in two Japanese-American women",
        "Methazolamide-induced Stevens-Johnson syndrome: a warning! Arch",
        "HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis",
        "Methazolamide-induced toxic epidermal necrolysis in a Chinese woman with HLA-B5901",
        "HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese",
        "CD8+ T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis",
        "Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review",
        "Adverse cutaneous reactions to phenobarbital in epileptic children",
        "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs The EuroSCAR-study",
        "Severe cutaneous reactions caused by barbiturates in seven Iranian children",
        "Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children",
        "Association of HLA genotypes with phenobarbital hypersensitivity in children",
        "Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}